The U.S. Department of Justice issued a final order on April 23, 2026, rescheduling FDA-approved marijuana drug products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, effective April 28 following Federal Register publication. This action, directed by Acting Attorney General Todd Blanche pursuant to President Trump's December 2025 executive order, provides immediate Section 280E tax relief and DEA registration pathways for qualifying medical operators while leaving recreational cannabis in Schedule I. DEA has scheduled an expedited administrative hearing from June 29 to July 15, 2026, to evaluate broader rescheduling, with a potential final rule by late July; parties must notify intent to participate by May 28. Legal challenges and congressional riders pose risks to implementation.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว$757,503 ปริมาณ
Mar 31, 2026
June 30
3%
December 31
25%
$757,503 ปริมาณ
June 30
$336,130 ปริมาณ
3%
December 31
$156,491 ปริมาณ
25%
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The U.S. Department of Justice issued a final order on April 23, 2026, rescheduling FDA-approved marijuana drug products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, effective April 28 following Federal Register publication. This action, directed by Acting Attorney General Todd Blanche pursuant to President Trump's December 2025 executive order, provides immediate Section 280E tax relief and DEA registration pathways for qualifying medical operators while leaving recreational cannabis in Schedule I. DEA has scheduled an expedited administrative hearing from June 29 to July 15, 2026, to evaluate broader rescheduling, with a potential final rule by late July; parties must notify intent to participate by May 28. Legal challenges and congressional riders pose risks to implementation.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ตลาดเปิดเมื่อ: Feb 7, 2026, 5:04 PM ET
ปริมาณการซื้อขาย
$757,503วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by March 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.The U.S. Department of Justice issued a final order on April 23, 2026, rescheduling FDA-approved marijuana drug products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, effective April 28 following Federal Register publication. This action, directed by Acting Attorney General Todd Blanche pursuant to President Trump's December 2025 executive order, provides immediate Section 280E tax relief and DEA registration pathways for qualifying medical operators while leaving recreational cannabis in Schedule I. DEA has scheduled an expedited administrative hearing from June 29 to July 15, 2026, to evaluate broader rescheduling, with a potential final rule by late July; parties must notify intent to participate by May 28. Legal challenges and congressional riders pose risks to implementation.
This market will resolve to "Yes" if marijuana is rescheduled down from I to any other level (or is unscheduled completely) by the Drug Enforcement Agency of the United States (https://www.dea.gov/drug-information/drug-scheduling), by June 30, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
ปริมาณการซื้อขาย
$757,503วันสิ้นสุด
Mar 31, 2026ตลาดเปิดเมื่อ
Feb 7, 2026, 5:04 PM ETResolver
0x65070BE91...The U.S. Department of Justice issued a final order on April 23, 2026, rescheduling FDA-approved marijuana drug products and state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act, effective April 28 following Federal Register publication. This action, directed by Acting Attorney General Todd Blanche pursuant to President Trump's December 2025 executive order, provides immediate Section 280E tax relief and DEA registration pathways for qualifying medical operators while leaving recreational cannabis in Schedule I. DEA has scheduled an expedited administrative hearing from June 29 to July 15, 2026, to evaluate broader rescheduling, with a potential final rule by late July; parties must notify intent to participate by May 28. Legal challenges and congressional riders pose risks to implementation.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย